Martínez-Sáez, Olga
Cortés, Javier
Ciruelos, Eva
Marín-Aguilera, Mercedes
González, Gloria
Paré, Laia
Herrera, Adriana
Villagrasa-González, Patricia
Prat, Aleix
Martín, Miguel http://orcid.org/0000-0001-9237-3231
Funding for this research was provided by:
Reveal Genomics
Article History
Received: 18 October 2023
Accepted: 12 February 2024
First Online: 23 April 2024
Declarations
:
: Potential conflicts of interest are the following: O.M.S reports advisory/consulting fees from Reveal Genomics, Roche and Astrazeneca and lecture fees from Daiichi Sankyo, Novartis and Eisai. J.C reports advisory/consulting fees from Roche, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp&Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon; honoraria from Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Steamline Therapeutics; institutional financial interests from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Iqvia, Queen Mary University of London; stockholder of MAJ3 Capital and Leuko (relative); and the patents WO 2014/199294 A and US 2019/ 0338368 A1. E.C. reports advisory/consulting fees from AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Roche, Seagen and lecture fees from Lilly,Novartis, Pfizer, Roche, Seagen and Gilead. M.M.A is an employee of Reveal Genomics. L.P is an employee of Reveal Genomics and listed as an inventor on patent PCT/ EP2021/070788. A.H. is an employee of Reveal Genomics. P.V.G is one of the stockholders of Reveal Genomics, also reports personal fees from NanoString and patents EP23382703 and EP23383369 PCT/EP2021/070788. AP reports advisory and consulting fees from Roche, Pfizer, Novartis, Amgen, Bristol-Myers Squibb, Puma, Oncolytics Biotech, MSD, Guardant Health, Peptomyc, and Lilly; lecture fees from Roche, Pfizer, Novartis, Amgen, Bristol-Myers Squibb, NanoString Technologies, and Daiichi-Sankyo; institutional financial interests from Boehringer, Novartis, Roche, NanoString, Sysmex Europa GmbH, Medica Scientia Innovation Research, SL, Celgene, Astellas, and Pfizer; is a stockholder and consultant of Reveal Genomics and SL; has the patent PCT/EP2016/080056 and the DNADX patent filed. M.M has received research grants from Roche, PUMA and Novartis; consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi Sankyo, Menarini/Stemline, and Pfizer and speakers’ honoraria from AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer. All other authors have declared no conflicts of interest.
: Not applicable.
: Not applicable.